Description
How It Works
GIP GLP-1 C20 , GIP GLP-1 , GIP GLP-1 GIP GLP-1 ,
Pharmacology
12.1 How It Works GIP GLP-1 C20 , GIP GLP-1 , GIP GLP-1 GIP GLP-1 ,
Dosage
2.1 MOUNJARO 2.5 mg [ Dosage (2.2)] , [ Precautions (5.6) (6.1)] 2.5 mg , 4 , 5 mg , 4 , 2.5 mg
Precautions
5.1 C 2 , , C [ (13.1)] MOUNJARO C , (MTC), C MOUNJARO MTC , MEN 2 MOUNJARO MTC ,
Contraindications
MOUNJARO MTC , 2 MEN 2 [ Precautions 5.1 ] MOUNJARO MOUNJARO , [ Precautions 5.4 ]
Drug Interactions
7.1 MOUNJARO , , [ Precautions (5.3)] 7.2 MOUNJARO , MOUNJARO , MOUNJARO
Adverse Reactions
Description C [ Precautions (5.1)] [ Precautions (5.2)] [ Precautions (5.3)] [ Precautions (5.4)] [ Precautions (5.5)] [ Precautions (5.6)] [ Precautions (5.7)] [ Precautions (5.8)]
Storage
16.1 MOUNJARO , , 4 1 1 1 , 4 NDC 1 NDC 2.5 mg/0.5 mL 0002-1506-80 0002-1152-01 5 mg/0.5 mL 0002-1495-80 0002-1243-01 7.5 mg/0.5 mL 0002-148
Indications
Used as an adjunct to diet and exercise to improve glycemic control in adults and children aged 10 years and older with type 2 diabetes.




